《滬深兩市》上證曾上3,100點 創板全日升3% 地產、旅遊、汽車及鋰電股造好
內地疫情持續緩和,內地昨日(10日)新增本土確診病例302例,新增本土無症狀感染者1,545例。人行今日(11日)進行100億元人民幣(下同)7天期逆回購操作,單日淨投放100億元。人民幣兌美元中間價今下調156點。
上證深成創板開市走勢各異,隨後公佈4月CPI升2.1%高於市場預期,憧憬美國政府有可能取消特朗普時期對中國產品加徵的部分關稅,A股各指數顯着上升,上證一度重上3,100點;創板一度大升逾5%,至尾市升幅略爲收窄至3%。
上證高見3,100點,全日升22點或0.8%,收報3,058點;深成指升196點或1.8%,收報11,109點;創業板指數反彈3%或69點,收報2,346點,成交2,183億元。上證深成全日成交逾萬億元,分別爲4,730億元及6,051億元。
中資金融股偏軟,工行(601398.SH)及建行(601939.SH)分別跌1.5%及0.7%。
地產及基建股持續造好,中交地產(000736.SZ)漲停。光大嘉寶(600622.SH)及信達地產(600657.SH)分別揚6.6%及3.9%。龍建股份(600853.SH)及宏潤建設(002062.SZ)續漲停。
汽車及鋰電股顯着反彈,長汽(601633.SH)漲停。比亞迪(002594.SZ)反彈8.3%。寧德時代(300750.SZ)揚8%,其4月電池裝車量5.08GWh,佔比38.28%。半導體股聞泰科技(600745.SH)漲停。隆基股份(601012.SH)升4.4%。
疫情顯着緩和,刺激部份旅遊及百貨股走高,雲南旅遊(002059.SZ)升近半成。衆信旅遊(002707.SZ)揚6.8%。
BioNTech或已在內地完成復必泰疫苗2期試驗,刺激復星醫藥(600196.SH)揚9.3%。其他新冠藥物概念股炒上,新華製藥(000756.SZ)漲停。華潤雙鶴(600062.SH)升5.5%。(ta/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.